News - Eli Lilly, Diabetes

Filter

Current filters:

Eli LillyDiabetes

Popular Filters

1 to 25 of 70 results

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Boehringer and Lilly re-file empagliflozin NDA with FDA

Boehringer and Lilly re-file empagliflozin NDA with FDA

19-06-2014

The US subsidiary of German family-owned drugmaker Boehringer Ingelheim and pharma major Eli Lilly have…

Boehringer IngelheimDiabetesEli LillyempagliflozinPharmaceuticalRegulationUSA

Boehringer and Lilly’s diabetes drug Jardiance gains EU approval

23-05-2014

German family-owned pharma major Boehringer Ingelheim and US partner Eli Lilly have received Marketing…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

13-05-2014

US pharma major Eli Lilly has released positive top-line results of three completed Phase III clinical…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

EMA/CHMP recommends empagliflozin for approval for type 2 diabetes

23-03-2014

German family-owned drug major Boehringer Ingelheim and partner Eli Lilly of the USA have announce a…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

05-03-2014

There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer…

Boehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaPharmaceuticalProductionRegulationUSA

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Sanofi sues Eli Lilly over Lantus patent infringement

Sanofi sues Eli Lilly over Lantus patent infringement

31-01-2014

French drug major Sanofi says it has filed a patent infringement suit against USA pharma firm Eli Lilly…

BiosimilarsDiabetesEli LillyLantusLegalNorth AmericaPatentsPharmaceuticalSanofiUSA

Global insulin market expanded to $20.8 billion in 2012

17-12-2013

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular…

Asia-PacificBayerChinaDiabetesEli LillyGlobalMarkets & MarketingNovo NordiskSanofi

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Survey aims to discover how early diabetes diagnoses can aid better outcomes

Survey aims to discover how early diabetes diagnoses can aid better outcomes

02-12-2013

A multinational survey of more than 10,000 people with type 2 diabetes has been launched by German family-owned…

Boehringer IngelheimDiabetesEli LillyGlobalPharmaceuticalResearch

Eli Lilly to invest further $700 million to boost insulin production

Eli Lilly to invest further $700 million to boost insulin production

14-11-2013

US pharma major Eli Lilly plans to invest more than $700 million to enhance its global insulin manufacturing…

DiabetesEli LillyFinancialPharmaceuticalProductionResearch

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients

07-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Cardiovascular risk a concern when prescribing diabetes treatments, survey finds

06-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) revealed that 79% of nearly 800 physicians in four Asian…

Asia-PacificBoehringer IngelheimDiabetesEli LillyHealthcarePharmaceuticalResearch

Type 2 diabetes market to reach $38.8 billion by 2019

25-10-2013

The global type 2 diabetes market is expected to expand from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

Geropharm to invest $45 million in Russian insulin production

Geropharm to invest $45 million in Russian insulin production

25-09-2013

Geropharm, one of Russia’s leading pharmaceutical and biotech companies, is establishing a plant for…

DiabetesEli LillyEuropeFinancialGeropharmNovo NordiskPharmaceuticalProductionSanofi

Novo Nordisk falls on loss of two US contracts

04-09-2013

Danish insulin giant Novo Nordisk (NOV: N) saw its shares fall 2.8% to 936 Danish kroner yesterday (September…

Bristol-Myers SquibbDiabetesEli LillyMarkets & MarketingNorth AmericaNovo NordiskNovoLogPharmaceuticalVictoza

Zealand and Lilly to work together on type 2 diabetes and obesity therapies

29-08-2013

Denmark's Zealand Pharma (Nasdaq OMX: ZEAL) has announced an exclusive peptide drug R&D collaboration…

DiabetesEli LillyGlobalPharmaceuticalResearchZealand Pharma

Positive Ph III data for Trajenta in elderly type 2 diabetes patients

15-08-2013

Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4)…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

Drug developed by UCSF researcher continues to show promise in type 1 diabetes

11-08-2013

Teplizumab, an experimental drug designed to block the advance of type 1 diabetes in its earliest stages…

DiabetesEli LillyPharmaceuticalResearchteplizumab

1 to 25 of 70 results

Back to top